Publications from EUnetHTA
Relative Effectiveness Assessments (REA) are health technology assessments consisting of four domains in the HTA Core Model®.
The EUnetHTA Rapid REAs include the following four domains:
- Health Problem and Current Use of the Technology
- Description and technical characteristics of technology
- Clinical Effectiveness
EUnetHTA decided to focus on these four elements because they are considered both important and transferable, i.e. usable in several countries. Besides these four domains, additional domains (i.e. economic evaluation, ethical, organisational, social and legal aspect of the introducing the technology) can be considered on a national level.
Joint Assessment on Pharmaceuticals
PTJA06 – Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant (13 February)
PTJA08 – Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity (13 February)
OTCA22 – POCT/ Point of care tests: D-DIMER AND TROPONIN (26 November)
Screening for osteoporosis in the general population. Summary . (16 September)
Ustekinumab for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic, or have medical contraindications to such therapies.This is a WP4 Joint Production.